Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Hematopoiesis: An Evolving Paradigm for Stem Cell Biology
Orkin, S. H., & Zon, L. I. (2008) · Cell · doi:10.1016/j.cell.2008.01.025 · Cited by 2,570
“1 and C/EBPa in myeloid leukemias (Mueller et al., 2002; Pabst et al., 2001), and Pax5 and other B cell factors (for example, E2A and EBF) in B-lymphoid leukemias (Mullighan et al.”
BackgroundCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
CCAAT/enhancer-binding proteins: structure, function and regulation
RAMJI, D. P., & FOKA, P. (2002) · Biochemical Journal · doi:10.1042/bj20020508 · Cited by 1,400
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C. M., Serve, H., Büchner, T., et al. (2002) · Blood · doi:10.1182/blood.v100.1.59 · Cited by 973
Self-citationPushing the limits of the scanning mechanism for initiation of translation
Kozak, M. (2002) · Gene · doi:10.1016/s0378-1119(02)01056-9 · Cited by 919
Fazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M. L., Nervi, C., & Bozzoni, I. (2005) · Cell · doi:10.1016/j.cell.2005.09.023 · Cited by 894
Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M. F., Haferlach, T., Hiddemann, W., & Falini, B. (2005) · Blood · doi:10.1182/blood-2005-06-2248 · Cited by 713
Self-citationChronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
Disruption of differentiation in human cancer: AML shows the way
Tenen, D. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc989 · Cited by 612
Self-citationTranscription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606
Self-citationWouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M., & Delwel, R. (2009) · Blood · doi:10.1182/blood-2008-09-179895 · Cited by 566
Falini, B., Nicoletti, I., Martelli, M. F., & Mecucci, C. (2007) · Blood · doi:10.1182/blood-2006-07-012252 · Cited by 565
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 552
Polycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
G ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Self-citationOstergaard, P., Simpson, M. A., Connell, F. C., Steward, C. G., Brice, G., Woollard, W. J., Dafou, D., Kilo, T., Smithson, S., Lunt, P., et al. (2011) · Nature Genetics · doi:10.1038/ng.923 · Cited by 506
Zhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M. L., Dayaram, T., Owens, B. M., Shigematsu, H., Levantini, E., Huettner, C. S., Lekstrom-Himes, J. A., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.006 · Cited by 504
Self-citationPreudhomme, C., Sagot, C., Boissel, N., Cayuela, J.-M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0990 · Cited by 501
AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G. (2001) · Nature Medicine · doi:10.1038/86515 · Cited by 463
“a the abnormalities were one del (9)(q22;q34); one t(6;9); one t(10;21)(p11;q22); one 8;one 14; and one complex aberrant karyotype.”
BackgroundSelf-citationFröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.060 · Cited by 458
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D., Ivey, A., & Huntly, B. J. P. (2016) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 445
Iwasaki, H., Somoza, C., Shigematsu, H., Duprez, E. A., Iwasaki-Arai, J., Mizuno, S.-I., Arinobu, Y., Geary, K., Zhang, P., Dayaram, T., et al. (2005) · Blood · doi:10.1182/blood-2005-03-0860 · Cited by 433
Self-citationNerlov, C. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.004 · Cited by 402
Sarry, J.-E., Murphy, K., Perry, R., Sanchez, P. V., Secreto, A., Keefer, C., Swider, C. R., Strzelecki, A.-C., Cavelier, C., Récher, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci41495 · Cited by 386
Intrinsic Requirement for Zinc Finger Transcription Factor Gfi-1 in Neutrophil Differentiation
Hock, H., Hamblen, M. J., Rooke, H. M., Traver, D., Bronson, R. T., Cameron, S., & Orkin, S. H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00501-0 · Cited by 384
“Recently, somatic mutations in C/EBP and Formally, we cannot dismiss an alternative model in PU.1 have been observed in human leukemias (Mueller which a proportion of Gfi-1 / Gr1 Mac1 cells repre- et al., 2002; Pabst et al., 2001).”
BackgroundTaskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307280 · Cited by 384
Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480228 · Cited by 381
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Differentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Hollink, I. H. I. M., van den Heuvel-Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Pratcorona, M., Abbas, S., Kuipers, J. E., van Galen, J. F., Beverloo, H. B., Sonneveld, E., Kaspers, G.-J. J. L., et al. (2011) · Blood · doi:10.1182/blood-2011-04-346643 · Cited by 334
Hematopoietic cytokines, transcription factors and lineage commitment
Zhu, J., & Emerson, S. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205318 · Cited by 330
“The di erential expression of C/EBPa appears to in¯uence the lineage choice of bi-potent G/M precursors to either granulocytic or monocytic direction, while PU.1 is needed for both (Anderson et al., 1998b) (Figure 3).”
BackgroundInfluentialMutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328
Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia
Mullican, S. E., Zhang, S., Konopleva, M., Ruvolo, V., Andreeff, M., Milbrandt, J., & Conneely, O. M. (2007) · Nature Medicine · doi:10.1038/nm1579 · Cited by 324
Shen, Y., Zhu, Y.-M., Fan, X., Shi, J.-Y., Wang, Q.-R., Yan, X.-J., Gu, Z.-H., Wang, Y.-Y., Chen, B., Jiang, C.-L., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343988 · Cited by 323
E2F Repression by C/EBPα Is Required for Adipogenesis and Granulopoiesis In Vivo
Porse, B. T., Pedersen, T. Å., Xu, X., Lindberg, B., Wewer, U. M., Friis-Hansen, L., & Nerlov, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00516-5 · Cited by 317
BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2
Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M. A., et al. (2002) · Nature Genetics · doi:10.1038/ng791 · Cited by 313
Molecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Implications of NRAS mutations in AML: a study of 2502 patients
Bacher, U., Haferlach, T., Schoch, C., Kern, W., & Schnittger, S. (2006) · Blood · doi:10.1182/blood-2005-08-3522 · Cited by 303
Self-citationMüller-Tidow, C., Steffen, B., Cauvet, T., Tickenbrock, L., Ji, P., Diederichs, S., Sargin, B., Köhler, G., Stelljes, M., Puccetti, E., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2890-2904.2004 · Cited by 303
Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Vukosavljevic, T., Paschka, P., Whitman, S. P., Langer, C., Baldus, C. D., Liu, C.-G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5554 · Cited by 302
“N-terminal nonsense mutations prevent expression of the full-length protein and result in a truncated isoform with dominant-negative activity, whereas the C-terminal mutations occurring in the bZIP domains are usually in-frame and encode mutant proteins lacking DNA binding and/or homodimerization activities.(19,20) Bo…”
BackgroundMizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298
Gombart, A. F., Hofmann, W.-K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S. H., Larsen, R. J., Asou, H., Miller, C. W., Hoelzer, D., et al. (2002) · Blood · doi:10.1182/blood.v99.4.1332 · Cited by 293
Dufour, A., Schneider, F., Metzeler, K. H., Hoster, E., Schneider, S., Zellmeier, E., Benthaus, T., Sauerland, M.-C., Berdel, W. E., Büchner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6010 · Cited by 293
Self-citationRainis, L. (2003) · Blood · doi:10.1182/blood-2002-11-3599 · Cited by 291
Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors
Johnson, P. F. (2005) · Journal of Cell Science · doi:10.1242/jcs.02459 · Cited by 288
“Experiments showing that reinstating C/EBPα expression in AML cells suppresses their proliferation in vitro and tumorigenicity in vivo support these conclusions (Truong et al., 2003).”
BackgroundInfluentialPulikkan, J. A., Dengler, V., Peramangalam, P. S., Peer Zada, A. A., Müller-Tidow, C., Bohlander, S. K., Tenen, D. G., & Behre, G. (2010) · Blood · doi:10.1182/blood-2009-08-240101 · Cited by 285
Self-citationC/EBPα mutations in acute myeloid leukaemias
Nerlov, C. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1363 · Cited by 280
Green, C. L., Koo, K. K., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2501 · Cited by 273
Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C., & Haferlach, T. (2011) · Blood · doi:10.1182/blood-2009-11-255976 · Cited by 265
Self-citationChoudhary, C., Schwäble, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W. E., Müller-Tidow, C., & Serve, H. (2005) · Blood · doi:10.1182/blood-2004-07-2942 · Cited by 263
Kirstetter, P., Schuster, M. B., Bereshchenko, O., Moore, S., Dvinge, H., Kurz, E., Theilgaard-Mönch, K., Månsson, R., Pedersen, T. Å., Pabst, T., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.008 · Cited by 251
Self-citationAlcalay, M., Meani, N., Gelmetti, V., Fantozzi, A., Fagioli, M., Orleth, A., Riganelli, D., Sebastiani, C., Cappelli, E., Casciari, C., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17595 · Cited by 249
Jendrzejewski, J., He, H., Radomska, H. S., Li, W., Tomsic, J., Liyanarachchi, S., Davuluri, R. V., Nagy, R., & de la Chapelle, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205654109 · Cited by 246
Self-citationVangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245
Self-citationHeterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
“1 mutations were not observed in the 10 M4 patients with inv(16), the 3 M2 patients with the t(8;21) AML1/ETO translocation, or in 11 M3 patients with the PML-RAR translocation.”
Self-citationTribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia
Keeshan, K., He, Y., Wouters, B. J., Shestova, O., Xu, L., Sai, H., Rodriguez, C. G., Maillard, I., Tobias, J. W., Valk, P., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.012 · Cited by 238
“Decreased C/EBPap42 levels are observed in diverse molecular subtypes of human AML (Helbling et al., 2004, 2005; Pabst et al., 2001a; Perrotti et al., 2002; Westendorf et al., 1998) and are sometimes associated with point mutations in C/EBPa (Pabst et al., 2001b).”
BackgroundRisk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
Bienz, M., Ludwig, M., Mueller, B. U., Oppliger Leibundgut, E., Ratschiller, D., Solenthaler, M., Fey, M. F., & Pabst, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1552 · Cited by 235
“For CEBPA mutational analysis, the entire coding region of the gene was amplified using three (A, B, and C) overlapping PCR primer pairs as previously described (7).”
MethodSelf-citationvan Waalwijk van Doorn-Khosrovani, S. B., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W. L. J., Valk, P. J. M., Berna Beverloo, H., Tenen, D. G., Löwenberg, B., & Delwel, R. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200216 · Cited by 235
Self-citationTumor suppressor genes in normal and malignant hematopoiesis
Krug, U., Ganser, A., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205322 · Cited by 231
“Recently, our group (Gombart et al., 2002) and others (Pabst et al., 2001) found mutations of C/EBPa in about 8% of AML and 2% of MDS samples.”
BackgroundIdentification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway
Tan, C., de Noronha, R. G., Roecker, A. J., Pyrzynska, B., Khwaja, F., Zhang, Z., Zhang, H., Teng, Q., Nicholson, A. C., Giannakakou, P., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.605.65.2 · Cited by 225
Akasaka, T., Balasas, T., Russell, L. J., Sugimoto, K.-J., Majid, A., Walewska, R., Karran, E. L., Brown, D. G., Cain, K., Harder, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-041012 · Cited by 215
Ho, P. A., Alonzo, T. A., Gerbing, R. B., Pollard, J., Stirewalt, D. L., Hurwitz, C., Heerema, N. A., Hirsch, B., Raimondi, S. C., Lange, B., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184747 · Cited by 215
Lin, L.-I., Chen, C.-Y., Lin, D.-T., Tsay, W., Tang, J.-L., Yeh, Y.-C., Shen, H.-L., Su, F.-H., Yao, M., Huang, S.-Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1816 · Cited by 214
“This 30kDa isoform has the capacity to further reduce wild-type C/ EBPa activity by inhibiting its DNA binding and transactivation of the target genes in a dominant-negative effect (10, 15).”
BackgroundResultDysregulation of the C/EBPα Differentiation Pathway in Human Cancer
Koschmieder, S., Halmos, B., Levantini, E., & Tenen, D. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9812 · Cited by 212
Self-citationMolecular genetics of human leukemias: New insights into therapy
Gilliland, D. G. (2002) · Seminars in Hematology · doi:10.1053/shem.2002.36921 · Cited by 203
Pabst, T., Eyholzer, M., Haefliger, S., Schardt, J., & Mueller, B. U. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5563 · Cited by 201
Self-citationMolecular Diagnosis of the Hematologic Cancers
Staudt, L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020067 · Cited by 200
Zhu, S., Yoon, K., Sterneck, E., Johnson, P. F., & Smart, R. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012437299 · Cited by 200
Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W., & Haferlach, T. (2010) · Blood · doi:10.1182/blood-2010-02-267955 · Cited by 199
Self-citationGATA1 in normal and malignant hematopoiesis
Crispino, J. D. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.11.002 · Cited by 199
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
Radomska, H. S., Bassères, D. S., Zheng, R., Zhang, P., Dayaram, T., Yamamoto, Y., Sternberg, D. W., Lokker, N., Giese, N. A., Bohlander, S. K., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052242 · Cited by 199
Self-citationShayegi, N., Kramer, M., Bornhäuser, M., Schaich, M., Schetelig, J., Platzbecker, U., Röllig, C., Heiderich, C., Landt, O., Ehninger, G., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461749 · Cited by 196
CEBPA point mutations in hematological malignancies
Leroy, H., Roumier, C., Huyghe, P., Biggio, V, Fenaux, P., & Preudhomme, C. (2005) · Leukemia · doi:10.1038/sj.leu.2403614 · Cited by 190
Familial myelodysplasia and acute myeloid leukaemia – a review
Owen, C., Barnett, M., & Fitzgibbon, J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06909.x · Cited by 187
“The 30-kD C/EBPa isoform lacks the first transactivating domain but retains the bZIP region required for dimerization and is thus able to dimerize with the wild-type 42-kD protein, potentially inhibiting its function in a dominant-negative manner (Pabst et al, 2001).”
BackgroundHow I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 182
Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia
Zhang, S.-J., Ma, L.-Y., Huang, Q.-H., Li, G., Gu, B.-W., Gao, X.-D., Shi, J.-Y., Wang, Y.-Y., Gao, L., Cai, X., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711824105 · Cited by 181
The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow
Bjerregaard, M. D., Jurlander, J., Klausen, P., Borregaard, N., & Cowland, J. B. (2003) · Blood · doi:10.1182/blood-2002-03-0835 · Cited by 179
The role of different genetic subtypes of CEBPA mutated AML
Fasan, A., Haferlach, C., Alpermann, T., Jeromin, S., Grossmann, V, Eder, C., Weissmann, S., Dicker, F., Kohlmann, A., Schindela, S., et al. (2014) · Leukemia · doi:10.1038/leu.2013.273 · Cited by 179
Self-citationTerminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
Sexauer, A., Perl, A., Yang, X., Borowitz, M., Gocke, C., Rajkhowa, T., Thiede, C., Frattini, M., Nybakken, G. E., Pratz, K., et al. (2012) · Blood · doi:10.1182/blood-2012-01-402545 · Cited by 179
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation
Patel, K. P., Ravandi, F., Ma, D., Paladugu, A., Barkoh, B. A., Medeiros, L. J., & Luthra, R. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpd7nr2rmnqdvf · Cited by 178
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
Heikamp, E., Henrich, J. A., Perner, F., Wong, E. M. C., Hatton, C., Wen, Y., Barwe, S. P., Gopalakrishnapillai, A., Xu, H., Uckelmann, H. J., et al. (2021) · Blood · doi:10.1182/blood.2021012806 · Cited by 179
de Guzman, C. G., Warren, A. J., Zhang, Z., Gartland, L., Erickson, P., Drabkin, H., Hiebert, S. W., & Klug, C. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5506-5517.2002 · Cited by 171
Advances in germline predisposition to acute leukaemias and myeloid neoplasms
Klco, J. M., & Mullighan, C. G. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00315-z · Cited by 153
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia
Gery, S., Gombart, A. F., Yi, W. S., Koeffler, C., Hofmann, W.-K., & Koeffler, H. P. (2005) · Blood · doi:10.1182/blood-2005-01-0358 · Cited by 168
Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation
Avellino, R., & Delwel, R. (2017) · Blood · doi:10.1182/blood-2016-09-687822 · Cited by 167
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome
Gurbuxani, S., Vyas, P., & Crispino, J. D. (2004) · Blood · doi:10.1182/blood-2003-05-1556 · Cited by 166
de Rooij, J. D. E., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Galen, J. F., Beverloo, H. B., Baruchel, A., Trka, J., Reinhardt, D., Sonneveld, E., Zimmermann, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.87 · Cited by 163
Pabst, T., Eyholzer, M., Fos, J., & Mueller, B. U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604977 · Cited by 163
“In AML patients, deregulation of CEBPA function is a common event comprising of genomic mutations (Pabst et al, 2001a; Frohling et al, 2004; Nerlov, 2004), transcriptional and posttranscriptional suppression (Pabst et al, 2001b; Helbling et al, 2004; Helbling et al, 2005), and inactivation by…”
BackgroundMethodSelf-citationTaube, F., Georgi, J. A., Kramer, M., Stasik, S., Middeke, J. M., Röllig, C., Krug, U., Krämer, A., Scholl, S., Hochhaus, A., et al. (2022) · Blood · doi:10.1182/blood.2020009680 · Cited by 162
Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C., & Kern, W. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.11.002 · Cited by 162
Zheng, R., Friedman, A. D., Levis, M., Li, L., Weir, E. G., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-06-1978 · Cited by 156
Nishizawa, H., Pryor-Koishi, K., Kato, T., Kowa, H., Kurahashi, H., & Udagawa, Y. (2007) · Placenta · doi:10.1016/j.placenta.2006.05.010 · Cited by 161
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.